Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
AbbVie submitted a new drug application to the FDA for its “3D” combination regimen of antivirals to treat adults with genotype 1 of...
Twelve weeks of daclatasvir, asunaprevir and BMS-791325 cured more than 90% of treatment-naive people with genotype 1 of hep C.
The hepatitis C pipeline: huge changes on the horizon
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.